1Zipitis CS, Akobeng A. Vitamin D supplementation in early child- hood and risk of type 1 diabetes : a systematic review and meta- analysis[J]. Arch Dis Child ,2008,93(6) :512-517.
3Gysemans CA, Cardozo AK, Callewaert H, et al. 1,25-Dihydro- xyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets:implication for prevention of diabetes in non- obese mice[J]. Endocrinology, 2005,146 (4) : 1956-1964.
4Mathieu C, Waer M, Casteels K, et al. Prevention of type I diabetes in NOD mice by nonhypercalcemic doses of a new structural ana- log of 1,25-dihydroxyvitamin D3,KH1060 [J]. Endocrinology, 1995,136 (3) : 866-872.
5Casteels KM, Mathieu C, Waer M, et al. Prevention of type I dia- betes in nonobese diabetic mice by late intervention with nonhy- percaleemic analogs of 1,25-dihydroxyvitamin D3 in combina- tion with a short induction course of eyelosporin A [J]. Endocri- nology, 1998,139( 1 ) :95-102.
6Gregori S, Giarratana N, Smiroldo S, et al. A 1 alpha, 25-dihydro- xyvitamin D (3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice[J]. Diabetes,2002,51 (5): 1367-1374.
7Kayaniyil S, Vieth R, Retnakaran R, et al. Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes[J]. Diabetes Care,2010,33 (6) : 1379-1381.
8Mitri J, Muraru MD, Pittas AG. Vitamin D and type 2 diabetes:a systematic review[J]. Eur J Clin Nutr,2011,65 (9):1005-1015.
9Hutchinson MS, Figenschau Y,Almgts B, et al. Serum 25-hydro- xyvitamin D levels in subjects with reduced glucose tolerance and type 2 diabetes-the Tromsφ OGTF-study [J]. Int J Vitam Nutr Res ,2011,81 (5) :317-327.
1Dawson HB, Heaney RP, Holick MF, et al. Estimates of optimal vitamin D stat us [J]. Osteoporos lnt, 2005, 16 (7):713-716.
2Pittas AG, Harris SS, Stark PC, et al. The effects of calcium and vitamin D supp lementation on blood glucose and markers of inflammation in non- diabetic adults [J]. Diabetes Care, 2007, 30 (4) : 980- 986.
3Zeitz U, Weber K, Soegiarto DW, et al. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor[J]. FASEB J, 2003, 17 (3): 509-511.
4Borissova AM, Tankova T, Kirilov G, et al. The effect of vitamin D3 on insulin secretion and peripheral insulin sensitivity in type 2 Diabetic patients[J]. Int J Clin Pract, 2003,57 (4) : 258-261.
5Chiu K C,Chu A, Go V L, et al. Hypovit aminosis D is associated with insulin re- sistance and beta cell dysfunction[J]. Am J ClinNutr, 2004, 79 (4) : 820-825.
6Ashraf A, Mick G, Meleth S, et al. Insulin treatment reduces pre-prandial plasma ghrelin concentrations in children with type 1 diabetes[J].Med Sci Monit, 2007, 13 (12) : 533-537.
7Soriano GL, BarriosV, Lechuga SA, et al. Response of circulating ghrelin levels to insulin therapy in children with newly di- agnosed type 1 diabetes mellitus[J]. Pediatr Res, 2004, 55 (5) : 830-835.
8Giulietti A, van EE, Overbergh L. Monocytes from type 2 diabetes patients have a pro-inflammatory profile. 1, 25-Di hydroxyvitamin D3 wokes as anti-inflammmatory [J]. Diabetes Res Clin Pract, 2007, 77 (1) : 47-57.
9Mager U, Lindi V, Lindstrom J,et al .Association of the Leu72Met polymorphism of the ghrelin gene with the risk of Type 2 diabetes in subjects with impaired glucose tolerance in the Finnish Diabetes Preven- tion Study [J]. Diabet Med, 2006,23 (6): 685-689.
10Wang TJ, Pencina MJ, Booth SL, et al.Vitamin D deficiency and risk of cardiovas cular disease[J]. Circulation 2008; 117(4) : 503-511.
